<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00445211</url>
  </required_header>
  <id_info>
    <org_study_id>2006-001</org_study_id>
    <nct_id>NCT00445211</nct_id>
  </id_info>
  <brief_title>HEROIC (Heparin Requirement in Counterpulsation)</brief_title>
  <acronym>HEROIC</acronym>
  <official_title>Heparin Requirement in Counterpulsation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>William Beaumont Hospitals</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>William Beaumont Hospitals</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Patients with intra-aortic balloon pumps (catheters placed in the groin connected to a pump
      which assists the heart by opening and closing a balloon in the aorta, thereby decreasing the
      work of the heart and improving blood flow to the coronary arteries) often receive
      intravenous (IV) heparin (a &quot;blood thinner&quot;) to prevent circulation problems in the leg
      (where they are inserted). When intra-aortic balloon pumps were initially developed, the
      catheters were larger than the catheters used today. Due to the large size of the catheter
      and the material used to make the catheter, it was thought that intravenous heparin would
      prevent poor blood flow to the leg that contained the temporary catheter. Intravenous
      heparin, however, has never been proven to maintain good blood flow in these patients. The
      catheters used with intra-aortic balloon pumps are now smaller in size and made of a material
      that is less likely to produce blood clots. It is not clear that heparin is needed with
      intra-aortic balloon pumps. Bleeding complications associated with intra-aortic balloon pumps
      may be decreased if heparin is not used. In 2004, 99 patients received intra-aortic balloon
      pumps in the cardiac catheterization labs at William Beaumont Hospital. These patients
      received intravenous heparin and experienced a large number of bleeding complications (27
      patients required a blood transfusion). This study will help the investigators to clarify if
      heparin should or should not be routinely used in patients with intra-aortic balloon pumps.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Potential patients will be identified in the cardiac catheterization lab when an intra-aortic
      balloon pump is placed. Patients who agree to participate in this study will be randomized
      (they will be selected to receive heparin or not to receive heparin with their intra-aortic
      balloon pump) by a process that is similar to flipping a coin. Patients will have a 50%
      chance of receiving heparin and a 50% chance of not receiving heparin. If a patient does not
      want to participate in the study, his/her cardiologist will decide if the patient will
      receive or not receive heparin. Intra-aortic balloon pumps have been used with and without
      intravenous heparin and there is no known increase in complications in patients who do not
      receive heparin. Risks include bleeding and possible blood clots/decreased blood flow to the
      leg with the catheter in both groups (due to different medical reasons). The patients in both
      groups will be monitored closely in the cardiac care unit while the intra-aortic balloon pump
      is in place to prevent and/or minimize complications.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    lack of enrollment
  </why_stopped>
  <start_date>January 2006</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Minor Ischemia (Decreased Blood Flow) During the Index Hospitalization</measure>
    <time_frame>0-4 days post surgery</time_frame>
    <description>Count of participants with decreased arterial flow in lower extremity as presented by diminished pulse that resolves with balloon removal, and not resulting in any impairment of body function</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Ischemia (Decreased Blood Flow) During the Index Hospitalization</measure>
    <time_frame>0-4 days post surgery</time_frame>
    <description>Count of participants with loss of Doppler signal or sensation or abnormal skin temperature, mottling or pallor in lower extremity requiring surgical intervention; or other major ischemic events including ischemic stroke; recurrent unstable ischemia (unstable angina, recurrent chest pain prompting definitive treatment such as re-percutaneous transluminal coronary angiography (PTCA), coronary artery bypass grafting (CABG), administration of thrombolytics); reinfarction including clinical symptoms or new ECG changes with creatine kinase (CK) elevation and positive creatine kinase-MB isoenzyme fraction; arterial thrombosis, embolus, dissection, or perforation; compartment syndrome; renal ischemia including new renal failure or need for dialysis; small bowel or splenic infarction; mesenteric or hepatic ischemia, or deep vein thrombosis.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Major Bleeding During the Index Hospitalization</measure>
    <time_frame>0-4 days post surgery</time_frame>
    <description>Count of participants with hemorrhage associated with at least one of the following features as defined by the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria: Bleeding that results in a decrease in hemoglobin &gt;/= 5g.dL or a hematocrit decrease of &gt;/= 15% of baseline value; bleeding that is intracranial (confirmed by MRI or CT); bleeding that results in death.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Intra-aortic Balloon Pump-related Death During the Index Hospitalization</measure>
    <time_frame>0-4 days post surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital Death During the Index Hospitalization</measure>
    <time_frame>0-4 post surgery</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">46</enrollment>
  <condition>Cardiogenic Shock</condition>
  <arm_group>
    <arm_group_label>Intra-Aortic balloon Pump with Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-Aortic Balloon Pump (IABP) with Heparin</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Intra-Aortic balloon Pump without Heparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Intra-Aortic balloon Pump (IABP) without Heparin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Heparin</intervention_name>
    <description>Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).</description>
    <arm_group_label>Intra-Aortic balloon Pump with Heparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Without Heparin</intervention_name>
    <description>Intra-Aortic balloon Pump (IABP) without Heparin.</description>
    <arm_group_label>Intra-Aortic balloon Pump without Heparin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt;/= 18 years

          -  Able to provide consent

          -  Insertion of Intra-aortic Balloon Pump (IABP) in William Beaumont Hospital (WBH) cath
             lab

          -  Anticipated duration of IABP &gt;/= 18 hours

        Exclusion Criteria:

          -  Contraindications to heparin

          -  Pre-existing condition requiring heparin administration (other than IABP)

          -  IABP placed outside of the WBH cardiac catheterization lab prophylactically for
             high-risk percutaneous coronary intervention (PCI), without complications)

          -  Pregnant women
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Justin Trivax, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>William Beaumont Hospitals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>William Beaumont Hospital</name>
      <address>
        <city>Royal Oak</city>
        <state>Michigan</state>
        <zip>48073</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Baim DS, Grossman W. Grossman's Cardiac Catheterization, Angiography and Intervention (6th Ed). Lippincott Williams &amp; Williams, Philadelphia, Pennsylvania, 2000, 463.</citation>
  </reference>
  <reference>
    <citation>MOULOPOULOS SD, TOPAZ S, KOLFF WJ. Diastolic balloon pumping (with carbon dioxide) in the aorta--a mechanical assistance to the failing circulation. Am Heart J. 1962 May;63:669-75.</citation>
    <PMID>14476645</PMID>
  </reference>
  <reference>
    <citation>Kantrowitz A. Origins of intraaortic balloon pumping. Ann Thorac Surg. 1990 Oct;50(4):672-4.</citation>
    <PMID>2222066</PMID>
  </reference>
  <reference>
    <citation>Stone GW, Ohman EM, Miller MF, Joseph DL, Christenson JT, Cohen M, Urban PM, Reddy RC. Contemporary utilization and outcomes of intra-aortic balloon counterpulsation. Am J Cardiol, 1993; 71:328-332.</citation>
  </reference>
  <reference>
    <citation>Cohen M, Dawson MS, Kopistansky C, McBride R. Sex and other predictors of intra-aortic balloon counterpulsation-related complications: prospective study of 1119 consecutive patients. Am Heart J. 2000 Feb;139(2 Pt 1):282-7.</citation>
    <PMID>10650301</PMID>
  </reference>
  <reference>
    <citation>Alle KM, White GH, Harris JP, May J, Baird D. Iatrogenic vascular trauma associated with intra-aortic balloon pumping: identification of risk factors. Am Surg. 1993 Dec;59(12):813-7.</citation>
    <PMID>8256934</PMID>
  </reference>
  <reference>
    <citation>Walls JT, Boley TM, Curtis JJ, Silver D. Heparin induced thrombocytopenia in patients undergoing intra-aortic balloon pumping after open heart surgery. ASAIO J. 1992 Jul-Sep;38(3):M574-6.</citation>
    <PMID>1457924</PMID>
  </reference>
  <reference>
    <citation>Ficek SJ, Stammers A, Deligonul U, Shurmur SW, Alonso A, Galbraith T. Hemostatic assessment of patients undergoing intraaortic balloon pump therapy. J Extra Corpor Technol. 1997 Jun;29(2):78-82.</citation>
    <PMID>10168534</PMID>
  </reference>
  <reference>
    <citation>Busch T, Sîrbu H, Zenker D, Dalichau H. Vascular complications related to intraaortic balloon counterpulsation: an analysis of ten years experience. Thorac Cardiovasc Surg. 1997 Apr;45(2):55-9.</citation>
    <PMID>9175219</PMID>
  </reference>
  <reference>
    <citation>Todd GJ, Bregman D, Voorhees AB, Reemtsma K. Vascular complications associated with percutaneous intra-aortic balloon pumping. Arch Surg. 1983 Aug;118(8):963-4.</citation>
    <PMID>6870526</PMID>
  </reference>
  <reference>
    <citation>Jiang CY, Zhao LL, Wang JA, Mohammod B. Anticoagulation therapy in intra-aortic balloon counterpulsation: does IABP really need anti-coagulation? J Zhejiang Univ Sci. 2003 Sep-Oct;4(5):607-11.</citation>
    <PMID>12958723</PMID>
  </reference>
  <reference>
    <citation>Sato K, Tokairin H, Kato M. [Two patients treated with intra-aortic balloon pump counterpulsation after subarachnoid hemorrhage]. Masui. 2001 Aug;50(8):859-62. Japanese.</citation>
    <PMID>11554017</PMID>
  </reference>
  <reference>
    <citation>Vonderheide RH, Thadhani R, Kuter DJ. Association of thrombocytopenia with the use of intra-aortic balloon pumps. Am J Med. 1998 Jul;105(1):27-32.</citation>
    <PMID>9688018</PMID>
  </reference>
  <reference>
    <citation>Schreiber TL, Kodali UR, O'Neill WW, Gangadharan V, Puchrowicz-Ochocki SB, Grines CL. Comparison of acute results of prophylactic intraaortic balloon pumping with cardiopulmonary support for percutaneous transluminal coronary angioplasty (PCTA). Cathet Cardiovasc Diagn. 1998 Oct;45(2):115-9.</citation>
    <PMID>9786386</PMID>
  </reference>
  <verification_date>April 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 6, 2007</study_first_submitted>
  <study_first_submitted_qc>March 7, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 8, 2007</study_first_posted>
  <results_first_submitted>April 11, 2017</results_first_submitted>
  <results_first_submitted_qc>April 11, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 19, 2017</results_first_posted>
  <last_update_submitted>April 11, 2017</last_update_submitted>
  <last_update_submitted_qc>April 11, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>William Beaumont Hospitals</investigator_affiliation>
    <investigator_full_name>Justin Trivax</investigator_full_name>
    <investigator_title>MD Cardiologist</investigator_title>
  </responsible_party>
  <keyword>Intraaortic balloon pumping</keyword>
  <keyword>Heparin</keyword>
  <keyword>Limb ischemia</keyword>
  <keyword>Bleeding</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Shock, Cardiogenic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcium heparin</mesh_term>
    <mesh_term>Heparin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Intra-Aortic Balloon Pump With Heparin</title>
          <description>Intra-Aortic Balloon Pump (IABP) with Heparin
Heparin: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).</description>
        </group>
        <group group_id="P2">
          <title>Intra-Aortic Balloon Pump Without Heparin</title>
          <description>Intra-Aortic balloon Pump (IABP) without Heparin
Without Heparin: Intra-Aortic balloon Pump (IABP) without Heparin.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="23"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Intra-Aortic Balloon Pump With Heparin</title>
          <description>Intra-Aortic Balloon Pump (IABP) with Heparin
Heparin: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).</description>
        </group>
        <group group_id="B2">
          <title>Intra-Aortic Balloon Pump Without Heparin</title>
          <description>Intra-Aortic balloon Pump (IABP) without Heparin
Without Heparin: Intra-Aortic balloon Pump (IABP) without Heparin.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="23"/>
            <count group_id="B2" value="23"/>
            <count group_id="B3" value="46"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <population>Only 8 patients analyzed in Heparin group and 9 patients in non-Heparin group; data not available for remaining patients.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <population>Only 8 patients analyzed in Heparin group and 9 patients in non-Heparin group; data not available for remaining patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="17"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Minor Ischemia (Decreased Blood Flow) During the Index Hospitalization</title>
        <description>Count of participants with decreased arterial flow in lower extremity as presented by diminished pulse that resolves with balloon removal, and not resulting in any impairment of body function</description>
        <time_frame>0-4 days post surgery</time_frame>
        <population>Only 8 patients analyzed in Heparin group and 9 patients in non-Heparin group; data not available for remaining patients</population>
        <group_list>
          <group group_id="O1">
            <title>Intra-Aortic Balloon Pump With Heparin</title>
            <description>Intra-Aortic Balloon Pump (IABP) with Heparin
Heparin: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).</description>
          </group>
          <group group_id="O2">
            <title>Intra-Aortic Balloon Pump Without Heparin</title>
            <description>Intra-Aortic balloon Pump (IABP) without Heparin
Without Heparin: Intra-Aortic balloon Pump (IABP) without Heparin.</description>
          </group>
        </group_list>
        <measure>
          <title>Minor Ischemia (Decreased Blood Flow) During the Index Hospitalization</title>
          <description>Count of participants with decreased arterial flow in lower extremity as presented by diminished pulse that resolves with balloon removal, and not resulting in any impairment of body function</description>
          <population>Only 8 patients analyzed in Heparin group and 9 patients in non-Heparin group; data not available for remaining patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Ischemia (Decreased Blood Flow) During the Index Hospitalization</title>
        <description>Count of participants with loss of Doppler signal or sensation or abnormal skin temperature, mottling or pallor in lower extremity requiring surgical intervention; or other major ischemic events including ischemic stroke; recurrent unstable ischemia (unstable angina, recurrent chest pain prompting definitive treatment such as re-percutaneous transluminal coronary angiography (PTCA), coronary artery bypass grafting (CABG), administration of thrombolytics); reinfarction including clinical symptoms or new ECG changes with creatine kinase (CK) elevation and positive creatine kinase-MB isoenzyme fraction; arterial thrombosis, embolus, dissection, or perforation; compartment syndrome; renal ischemia including new renal failure or need for dialysis; small bowel or splenic infarction; mesenteric or hepatic ischemia, or deep vein thrombosis.</description>
        <time_frame>0-4 days post surgery</time_frame>
        <population>Only 8 patients analyzed in Heparin group and 9 patients in non-Heparin group; data not available for remaining patients</population>
        <group_list>
          <group group_id="O1">
            <title>Intra-Aortic Balloon Pump With Heparin</title>
            <description>Intra-Aortic Balloon Pump (IABP) with Heparin
Heparin: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).</description>
          </group>
          <group group_id="O2">
            <title>Intra-Aortic Balloon Pump Without Heparin</title>
            <description>Intra-Aortic balloon Pump (IABP) without Heparin
Without Heparin: Intra-Aortic balloon Pump (IABP) without Heparin.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Ischemia (Decreased Blood Flow) During the Index Hospitalization</title>
          <description>Count of participants with loss of Doppler signal or sensation or abnormal skin temperature, mottling or pallor in lower extremity requiring surgical intervention; or other major ischemic events including ischemic stroke; recurrent unstable ischemia (unstable angina, recurrent chest pain prompting definitive treatment such as re-percutaneous transluminal coronary angiography (PTCA), coronary artery bypass grafting (CABG), administration of thrombolytics); reinfarction including clinical symptoms or new ECG changes with creatine kinase (CK) elevation and positive creatine kinase-MB isoenzyme fraction; arterial thrombosis, embolus, dissection, or perforation; compartment syndrome; renal ischemia including new renal failure or need for dialysis; small bowel or splenic infarction; mesenteric or hepatic ischemia, or deep vein thrombosis.</description>
          <population>Only 8 patients analyzed in Heparin group and 9 patients in non-Heparin group; data not available for remaining patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Major Bleeding During the Index Hospitalization</title>
        <description>Count of participants with hemorrhage associated with at least one of the following features as defined by the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria: Bleeding that results in a decrease in hemoglobin &gt;/= 5g.dL or a hematocrit decrease of &gt;/= 15% of baseline value; bleeding that is intracranial (confirmed by MRI or CT); bleeding that results in death.</description>
        <time_frame>0-4 days post surgery</time_frame>
        <population>Only 8 patients analyzed in Heparin group and 9 patients in non-Heparin group; data not available for remaining patients</population>
        <group_list>
          <group group_id="O1">
            <title>Intra-Aortic Balloon Pump With Heparin</title>
            <description>Intra-Aortic Balloon Pump (IABP) with Heparin
Heparin: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).</description>
          </group>
          <group group_id="O2">
            <title>Intra-Aortic Balloon Pump Without Heparin</title>
            <description>Intra-Aortic balloon Pump (IABP) without Heparin
Without Heparin: Intra-Aortic balloon Pump (IABP) without Heparin.</description>
          </group>
        </group_list>
        <measure>
          <title>Major Bleeding During the Index Hospitalization</title>
          <description>Count of participants with hemorrhage associated with at least one of the following features as defined by the Thrombolysis in Myocardial Infarction (TIMI) Study Group criteria: Bleeding that results in a decrease in hemoglobin &gt;/= 5g.dL or a hematocrit decrease of &gt;/= 15% of baseline value; bleeding that is intracranial (confirmed by MRI or CT); bleeding that results in death.</description>
          <population>Only 8 patients analyzed in Heparin group and 9 patients in non-Heparin group; data not available for remaining patients</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="8"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Intra-aortic Balloon Pump-related Death During the Index Hospitalization</title>
        <time_frame>0-4 days post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intra-Aortic Balloon Pump With Heparin</title>
            <description>Intra-Aortic Balloon Pump (IABP) with Heparin
Heparin: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).</description>
          </group>
          <group group_id="O2">
            <title>Intra-Aortic Balloon Pump Without Heparin</title>
            <description>Intra-Aortic balloon Pump (IABP) without Heparin
Without Heparin: Intra-Aortic balloon Pump (IABP) without Heparin.</description>
          </group>
        </group_list>
        <measure>
          <title>Intra-aortic Balloon Pump-related Death During the Index Hospitalization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Hospital Death During the Index Hospitalization</title>
        <time_frame>0-4 post surgery</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Intra-Aortic Balloon Pump With Heparin</title>
            <description>Intra-Aortic Balloon Pump (IABP) with Heparin
Heparin: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).</description>
          </group>
          <group group_id="O2">
            <title>Intra-Aortic Balloon Pump Without Heparin</title>
            <description>Intra-Aortic balloon Pump (IABP) without Heparin
Without Heparin: Intra-Aortic balloon Pump (IABP) without Heparin.</description>
          </group>
        </group_list>
        <measure>
          <title>Hospital Death During the Index Hospitalization</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="23"/>
                <count group_id="O2" value="23"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Time IntraAortic Balloon Pump (IABP) was inserted in the catheterization laboratory to length of stay in hospital.. 0-4 days</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Intra-Aortic Balloon Pump With Heparin</title>
          <description>Intra-Aortic Balloon Pump (IABP) with Heparin
Heparin: Heparin administered at 500units/hour while on Intra-Aortic balloon Pump (IABP).</description>
        </group>
        <group group_id="E2">
          <title>Intra-Aortic Balloon Pump Without Heparin</title>
          <description>Intra-Aortic balloon Pump (IABP) without Heparin
Without Heparin: Intra-Aortic balloon Pump (IABP) without Heparin.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="23"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="23"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small number of subjects analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Justin Trivax</name_or_title>
      <organization>William Beaumont Hospital</organization>
      <phone>(248)587-2300</phone>
      <email>Justin.Trivax@beaumont.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

